AF-353

• UNSPSC Description:

  AF-353 (Ro-4) is a potent, selective and orally bioavailable P2X3/P2X2/3 receptor antagonist, with a pIC50 of 8.0 for both human and rat P2X3, and with a pIC50 of 7.3 for human P2X2/3[1][2].

• Target Antigen:

  P2X Receptor

• Type:

  Reference compound

• Related Pathways:

  Membrane Transporter/Ion Channel

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/AF-353.html

• Solubility:

  DMSO : 83.33 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C(I)C(OC)=C1

• Molecular Weight:

  400.21

• References & Citations:

  [1]Gever JR, et al. AF-353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist. Br J Pharmacol. 2010 Jul;160(6):1387-1398.|[2]Munoz A, et al. Modulation of bladder afferent signals in normal and spinal cord-injured rats by purinergic P2X3 and P2X2/3receptors. BJU Int. 2012 Oct;110(8 Pt B):E409-414.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  865305-30-2